iShares MSCI Canada (TSX) vs Sana Biotechnology Inc — how do they compare? iShares MSCI Canada (TSX) trades at $61.82, while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: iShares MSCI Canada (TSX) is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| EWC | SANA | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $61.51 | $5.92 |
52-Week Low | $47.00 | $2.68 |
Market Cap | — | $1.13B |
Enterprise Value | — | $1.05B |
Signals from Pluang's Aura AI — not financial advice
EWC trades at $61.77, up 0.44% today, with a bullish technical signal from moving averages but overbought RSI levels. The ETF shows strong 2026 performance, though trailing the S&P 500, and faces trade tensions as U.S. tariffs on Canadian goods loom, potentially impacting exports excluding energy and potash.
Outlook is mixed: growth drivers include Canada's record exports and active ETF trends, but risks from tariff escalations and political uncertainty weigh. Investors balance double-digit returns against trade war volatility, with key support at $61.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Trailing returns across standard periods
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →